scholarly article | Q13442814 |
P356 | DOI | 10.1182/BLOOD.2019004492 |
P698 | PubMed publication ID | 32206772 |
P50 | author | Barbara Eichhorst | Q47158788 |
Stephan Stilgenbauer | Q47158807 | ||
Jasmin Bahlo | Q108428543 | ||
P2093 | author name string | Karl-Anton Kreuzer | |
Michael Hallek | |||
Hartmut Döhner | |||
Lars Bullinger | |||
Christof Schneider | |||
Michael Kneba | |||
Anna Dolnik | |||
Daniel Mertens | |||
Eugen Tausch | |||
Can Zhang | |||
Kirsten Fischer | |||
Yanwen Jiang | |||
Matthias Ritgen | |||
Othman Al-Sawaf | |||
Johannes Bloehdorn | |||
Kathryn Humphrey | |||
Sandra Robrecht | |||
Maneesh Tandon | |||
William Schary | |||
Anna Maria Fink | |||
Michele Porro Lurà | |||
P577 | publication date | 2020-03-23 | |
P1433 | published in | Blood | Q885070 |
P1476 | title | Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax |
Q99557890 | Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia |
Q98953060 | Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial |
Search more.